Therapeutic persistence with infliximab was associated with signifi cantly fewer ulcerative colitis patients requiring hospitalization; once hospitalized, patients with therapeutic persistence had ...

At 52 weeks, there was no significant difference in clinical remission (82.3% vs 77.4%, respectively) or steroid-free clinical remission (84.8% vs 83.1%), but more patients taking vedolizumab achieved ...

While infliximab (Remicade) and vedolizumab (Entyvio) were comparable for clinical remission in previously biologic-naive ulcerative colitis patients, infliximab was more likely to result in ...

A new study found cyclosporine was no more effective than infliximab in patients with acute, severe ulcerative colitis refractory to intravenous steroids, according to a report by Internal Medicine ...

Please provide your email address to receive an email when new articles are posted on . In a multicenter, open-label trial, researchers investigated the outcomes of discontinued infliximab use in ...

ROCHESTER, Minn -- A new study led by Mayo Clinic researchers has found that ulcerative colitis patients had a 41 percent reduction in colectomy after a year when treated with infliximab, according to ...

In good news for patients with stubborn cases of ulcerative colitis, a serious intestinal disorder, a new research review suggests that the drug infliximab can be a useful alternative if other ...

JERSEY CITY, N.J., May 21, 2024 /PRNewswire/ -- Celltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) ...

ZYMFENTRA™ is the first FDA-approved subcutaneous infliximab for the treatment of moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease ZYMFENTRA™ is ...

Please provide your email address to receive an email when new articles are posted on . Infliximab induction and maintenance were associated with “potentially improved efficacy outcomes” vs.

Credit: Getty Images What have we learned in recent years about the safety and efficacy of different biologics for the treatment of ulcerative colitis? Ulcerative colitis (UC) is a condition with a ...

Interleukin-23 (IL-23) plays a pivotal role in the complex pathogenesis of both ulcerative colitis and Crohn's disease, making it a promising therapeutic target.1 Mirikizumab is a humanised IgG4 ...